Affitope AD01

Drug Profile

Affitope AD01

Alternative Names: AD 01 - AFFiRiS; AD-1; Alzheimer AD01

Latest Information Update: 25 Nov 2009

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AFFiRiS
  • Class Alzheimer vaccines; Antidementias
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Suspended Alzheimer's disease

Most Recent Events

  • 19 Nov 2009 Suspended - Phase-I for Alzheimer's disease in Austria (SC)
  • 20 Oct 2009 A phase I trial met its primary endpoint of safety and tolerability in patients with Alzheimer's disease
  • 16 Sep 2009 Interim adverse events data from phase I trials in Alzheimer's disease presented at the 22nd Annual Congress of the European College of Neuropsychopharmacology (ECNP-2009)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top